Clinical Trials

Search Results 11-14 of 14 for NSCLC

Results filtered:
Study status: Open/Status Unknown

Edit search filters

An Open-label Multi-Cohort Phase 1b/2 Study To Evaluate The Safety, Efficacy, And Optimal Dose Of Telisotuzumab Adizutecan In Combination With A PD-1 Immune Checkpoint Inhibitor In Advanced Or Metastatic Non-Squamous NSCLC With No Prior Treatment For Advanced Disease And No Actionable Genomic Alterations (AndroMETa-Lung-536)

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

An Open-label Multi-Cohort Phase 1b/2 Study To Evaluate The Safety, Efficacy, And Optimal Dose Of Telisotuzumab Adizutecan In Combination With A PD-1 Immune Checkpoint Inhibitor In Advanced Or Metastatic Non-Squamous NSCLC With No Prior Treatment For Advanced Disease And No Actionable Genomic Alterations (AndroMETa-Lung-536)

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC. ABBV-400 and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of ABBV-400 in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 4 treatment groups. Two groups will receive budigalimab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive budigalimab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by budigalimab and pemetrexed. One group will receive the standard of care (SOC) pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 172 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with budigalimab or receive IV budigalimab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by budigalimab and pemetrexed, or IV SOC pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Contact us for the latest status	View complete study & contact information
Rochester, Minn.	Contact us for the latest status
Scottsdale/Phoenix, Ariz.	Contact us for the latest status

Print study details

Site IRB:
- Jacksonville, Florida: 26-001289
- Rochester, Minnesota: 26-001289
- Scottsdale/Phoenix, Arizona: 26-001289
NCT ID:
NCT06772623
Sponsor Protocol Number:
M24-536

Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with Cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. Currently the study is enrolling only to the HNSCC cohort.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Contact us for the latest status	View complete study & contact information
Scottsdale/Phoenix, Ariz.	Contact us for the latest status
Jacksonville, Fla.	Contact us for the latest status

Print study details

Site IRB:
- Rochester, Minnesota: 20-000573
- Scottsdale/Phoenix, Arizona: 20-000573
- Jacksonville, Florida: 20-000573
NCT ID:
NCT04291105
Sponsor Protocol Number:
VYR-VSV2-203

An Adjuvant Study To Evaluate SMS001 (Paclitaxel) In Non-Small Cell Lung Cancer

Rochester, MN
- See Details
An Adjuvant Study To Evaluate SMS001 (Paclitaxel) In Non-Small Cell Lung Cancer
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Open for enrollment
View complete study & contact information

Print study details
Site IRB:
Rochester, Minnesota: 23-008879

NCT ID:
NCT06693336

Sponsor Protocol Number:
132551-1
A Study Of VENTANA TROP2 (EPR20043) Device In Non-Small Cell Lung Cancer (NSCLC)

Rochester, MN
- See Details
A Study Of VENTANA TROP2 (EPR20043) Device In Non-Small Cell Lung Cancer (NSCLC)
- Study phase:
  0
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

The purpose of this study is to evaluate the inter-laboratory site and reader variability of the VENTANA TROP2 (EPR20043) Device, RUO used with OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument and DP 200/DP 600 scanners in determining the TROP2 expression level in FFPE NSCLC.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Contact us for the latest status
View complete study & contact information

Print study details
Site IRB:
Rochester, Minnesota: 25-005162

Sponsor Protocol Number:
D209266

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information

Pagination Clinical studies

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 11-14 of 14 for NSCLC

Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients

An Adjuvant Study To Evaluate SMS001 (Paclitaxel) In Non-Small Cell Lung Cancer

A Study Of VENTANA TROP2 (EPR20043) Device In Non-Small Cell Lung Cancer (NSCLC)

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions